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Abstract 
Bovine papillomavirus (BPV) infections of equine species have a central role in the aetiology of equine sarcoids; a 
common benign skin tumour of horses, zebras and donkeys. Within the lesions, all of the early papillomavirus genes 
are expressed and promote the excessive replication of fibroblasts which characterise these tumours. Equine sarcoids 
differ from BPV induced fibro-papillomas of cattle (the natural host of BPV), in that they do not produce high amounts 
of virus particles, do not usually regress spontaneously and do not sero-convert to BPV; features which suggest 
that affected horses lack an effective anti-viral immune response to BPV. Equine sarcoids contain large numbers of 
CD4+ CD8+ dual positive T-cells which uniformly express FOXP3, the key transcription factor of regulatory T-cells, 
and FOXP3 is also expressed within the BPV infected fibroblasts. Compared to healthy skin, sarcoids showed increased 
mRNA transcription for FOXP3 and the regulatory cytokine TGFβ. Transcription of IL17, which has been shown to have 
a regulatory function in human papillomavirus-associated tumours, was also elevated in equine sarcoids compared 
to spleen. In contrast, the levels of mRNA transcripts for effector T cell cytokines IL2, IL4 and interferon-gamma (IFNγ) 
were not elevated in sarcoids compared to healthy skin or spleen. Similarly neither interferon-alpha (IFNα), interferon-
beta (IFNβ) nor IL12 family members were elevated in sarcoids compared to normal skin. We suggest that the regula-
tory cytokine micro-environment within sarcoids enables the persistence of the lesions by preventing an effective 
anti-viral immune response.
© 2016 Wilson and Hicks. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Papillomaviruses are among the most widespread of 
animal viruses, with many hosts harbouring multiple 
virus types. Phylogenetic studies show that the papil-
lomaviruses within a specific host often have a degree 
of similarity, indicating that host and virus have co-
evolved over a prolonged period of time during which 
new variants slowly emerged as mutations accumulated 
within the virus genome [1]. Accordingly, it is assumed 
that the majority of papillomaviruses are host-specific 
and do not readily cross species barriers. However, phy-
logenetic studies have also revealed cases where closely 
related papillomavirus are found in separate host spe-
cies indicating that transfer of papillomavirus infections 
across species does occur and may lead to the [more 
rapid] emergence of new papillomavirus types [1]. Bovine 
papillomavirus 1 and 2 (BPV1, BPV2) provide examples 
of cross species infection, in that both virus types cause 
fibropapilloma lesions in cattle (Bos taurus) and are also 
associated with the occurrence of sarcoids in domes-
tic horses (Equus caballus), donkeys (Equus asinus) and 
zebras (Equus zebra) [2–4]. In equine spp. sarcoids is a 
collective term for a group of non-resolving pathological 
skin lesions, characterised by proliferation of fibroblasts 
along with the presence of DNA from BPV1 or BPV2: 
together these lesions comprise the commonest skin 
tumours in equines [5].
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The exact nature of the link between BPV and sarcoids 
has proved controversial as electron microscopy stud-
ies and immunohistology of formalin fixed tissues which 
detect virus particles and late virus proteins in bovine 
fibropapillomas; have consistently failed to demonstrate 
the presence of BPV capsids or late proteins within sar-
coids [6–9].
Early attempts to transmit BPV by directly inoculat-
ing cell free papilloma material derived from cattle into 
horses did indeed induce lesions characterised by fibro-
blast proliferation which morphologically resembled 
sarcoids. However, BPV could not generally be passaged 
from these sarcoid type lesions into new horses [10, 11] 
indicating an absence of continuing infectious virus par-
ticle production. In contrast, lesions of cattle infected 
with either BPV1 or BPV2 contain large numbers of virus 
particles [8], which when isolated can readily be trans-
mitted to new hosts in vivo [12]. Similarly, transmission 
studies using material taken from equine sarcoids found 
that while explants of sarcoid tissue could sometimes 
be transmitted within and between equine hosts, injec-
tion of cell free supernatants or minced sarcoid mate-
rial between horses did not reliably transmit sarcoids 
and was only occasionally successful when the material 
was introduced to scarified skin [13]. Overall the experi-
ments could not clearly distinguish between the de-novo 
transfer of infectious virus between equine hosts and the 
reactivation of established latent papillomavirus infection 
subsequent to scarification such as has been described in 
cattle [3].
The lesions produced by experimental inoculation of 
horses with BPV particles derived from cattle regressed 
spontaneously after several weeks [10, 11] in the same 
manner as naturally occurring BPV fibropapillomas in 
cattle, which resolve spontaneously after several months 
in association with the appearance of tumour infiltrat-
ing leukocytes [3, 14]. In contrast, naturally occurring 
sarcoids in horses typically persist indefinitely and fre-
quently re-grow following surgical removal [15]. Early 
experiments showed that regression of experimental sar-
coids induced following inoculation of horses with BPV 
derived from cattle was accompanied by the appearance 
of antibodies to BPV, yet no anti-BPV antibodies were 
seen in naturally occurring sarcoids, observations which 
at the time caused the authors to cast doubt on the role of 
BPV in the aetiology of equine sarcoids [16, 17]. Never-
theless, sarcoids invariably contain BPV1 or BPV2 DNA, 
present as an un-integrated episome [18] and several 
early transforming papillomavirus proteins are expressed 
in sarcoid tissues, supporting the role of BPV as the 
aetiological agent responsible for sarcoids [9, 19–21]. In 
addition, mRNA transcripts encoding both early and late 
virus proteins have been detected by RT-PCR of equine 
sarcoid tissues [9, 22], although neither study showed the 
late gene mRNA to be in the form of a correctly spliced 
transcript that could be translated into a functional 
protein. In cattle, late protein synthesis and productive 
virus infection takes place at the junction between the 
upper stratum spinosum and keratinised layers of the 
epidermis [9, 23]. Two studies have reported the detec-
tion of late BPV capsid antigen expression in a minority 
of equine sarcoids stained by immunofluorescence using 
frozen sections [9, 19], but as neither study showed the 
clear nuclear staining that is seen in other productive 
papillomavirus infections the results remain inconclu-
sive. Localisation of BPV DNA by in  situ hybridisation 
detected virus exclusively in the fibroblasts and not in 
the overlying epidermis [24], in contradiction later PCR 
studies showed BPV DNA to be present throughout the 
epidermal layers of equine sarcoids [19, 25]. However a 
recent study using a highly sensitive amplified in  situ 
hybridisation technique also failed to detect viral nucleic 
acid within the nuclei of epidermal cells overlying sarcoid 
lesions in the majority of cases, while once again BPV 
nucleic acid was invariably present in the fibroblast lay-
ers [26]. Interestingly, in just a few cases BPV positive 
nuclei were seen in scattered epidermal cells as well as 
in sebocytes and apocrine sweat glands [26], locations 
not previously associated with papillomavirus infection. 
Small amounts of BPV DNA combined with late virus 
protein have been detected in a subset of sarcoid cases by 
immuno-capture PCR using antibodies specific for BPV 
capsid antigens [27] providing possible evidence for trace 
amounts of DNA containing virus particles within a sub-
set of equine sarcoids.
Despite the lack of conclusive evidence for efficient 
production of infectious BPV virions in sarcoids, analysis 
of the genomes of BPV1 present in sarcoids has shown 
distinct equine associated sequence variations within the 
E5, E2 genes and long control regions [28, 29], moreover 
BPV1-DNA isolated from horses consistently contained a 
deletion of four residues from within the L2 protein that 
may also indicate a distinctive equine sub-type of BPV1 
has evolved [9]. The evolution and maintenance of such 
equine specific variants would require sequential passage 
of BPV through horses, yet to date the evidence for pro-
ductive virus evidence remains scant. One explanation 
that could reconcile the conflicting lines of evidence is 
that the prolonged survival of sarcoids, in which produc-
tion of virus particles is intermittent or falls below the 
limit of detection by conventional immune-histology or 
electron microscopy, would nonetheless permit a mini-
mal transfer of virus between horses (basic reproduc-
tion number R0  ≥1) sufficient to sustain an endemic 
infection. However, persistent infection requires a fur-
ther conjecture to account for the failure of the immune 
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system of horses to eliminate the virus compared to BPV 
lesions of cattle [3, 14].
The demonstration that BPV E5 protein can inhibit 
the surface expression of MHC class I [30], and that BPV 
early genes also down-regulate TLR4 expression [31] 
provide mechanisms for immune evasion which go some 
way to explaining sarcoid persistence, but leaves the 
problem of explaining why BPV E5 does not act in a simi-
lar manner to prevent ultimate regression of papillomas 
in their natural bovine host. Further evidence for a sup-
pressed immune response contributing to sarcoid persis-
tence in horses has recently been provided by a study in 
which mRNA encoding the regulatory T-cell transcrip-
tion factor FOXP3 along with certain other cytokines 
were shown to be elevated within sarcoid tumours [32].
In this paper prompted by our earlier observation that 
sarcoid tissue is infiltrated by large numbers of T-cells 
[9] we further examine the proposition that the cytokine 
micro-environment and infiltrating regulatory T-cells 
have a role in blocking the clearance of virus infected 
cells from sarcoids, thereby facilitating the ultimate 
transmission of virus between horses and enabling the 
evolution of equine specific BPV variants.
Materials and methods
Sample collection
Formalin-fixed and paraffin wax-embedded samples of 
sarcoid tissue were retrieved from the pathology archive 
of the University of Bristol, School of Veterinary Sciences. 
Fresh sarcoid material was collected from six horses dur-
ing surgical removal or immediately post mortem; tissues 
were embedded in optimal cutting temperature (OCT) 
medium and snap frozen in isopentane cooled over liquid 
nitrogen, before storage at −70 °C.
Additional material from six fresh sarcoids, was placed 
in RNAlater® (Invitrogen, UK) stored for 48  h at 4  °C 
and then kept at −70  °C until used. For comparison six 
samples of spleen and six samples of healthy skin (from 
horses without sarcoid lesions) were collected post mor-
tem from an abattoir, placed immediately in RNAlater, 
then taken to the laboratory for processing.
Immunohistology
Formalin fixed tissue samples were stained using rab-
bit anti-CD3, biotinylated donkey anti-rabbit and avi-
din biotin peroxidase conjugate as previously described 
[9] FOXP3 expression was detected using either 1:400 
affinity purified polyclonal rabbit anti-FOXP3 (ab10563 
abCam, UK) which maps to an epitope at the extreme 
C-terminal of human and equine FOXP3 or monoclonal 
rat anti mouse Foxp3 (FJK-16 s eBioscience) which maps 
to an epitope between residues 75-125 in the region 
of exon2 of murine Foxp3. For both antibodies heat 
treatment in Tris–EDTA pH 9.0 was used for antigen 
recovery. For immunofluorescence the primary antibod-
ies used were 3H5 monoclonal mouse anti-BPV E2 (1 μg/
mL) [33], and rabbit anti-CD3 (diluted 1:400; A0452 
Dako), 1:400 polyclonal rabbit anti-FOXP3 (ab10563 
abCam UK), 1  μg/mL monoclonal mouse anti-equine 
CD4 (HB61A), CD8 (73/6.9.1), MHC I (H58A) and MHC 
II H34A) (Kingfisher Biotec). Control sections were 
incubated with normal rabbit immunoglobulins (diluted 
1:400; XO936 Dako), or an isotype matched monoclo-
nal antibody in place of the primary antibody. Second-
ary antibodies were affinity-purified Fab fragments of 
donkey FITC-anti-mouse or FITC anti-rat and texas red 
anti-rabbit immunoglobulins absorbed against multiple 
species serum proteins; (Jackson Immunoresearch) used 
at 1:1000 dilution. For dual staining with primary mouse 
monoclonal antibodies, FITC or TRITC conjugated to 
goat anti-mouse sub-class specific polyclonal antibodies 
were used at a dilution of 1:100 (Southern-Biotech). For 
immunofluorescence staining 6 μm thick frozen sections 
were cut and mounted onto slides coated with chrome 
alum gelatine, air dried, then fixed in 100% acetone for 
5 min at room temperature. Individually wrapped slides 
were stored at −70 °C prior to use. Sections were equili-
brated to room temperature before unwrapping, then 
re-hydrated in PBS and non-specific protein binding 
blocked by incubation in PBS with 10% horse serum. 
Sections were stained with combinations of rabbit and 
mouse primary antibodies diluted in PBS with 10% horse 
serum, washed in PBS, followed by the appropriate flo-
rescent conjugate antibodies. Slides were mounted in 
Vectashield® DAPI aqueous mounting medium (Vector 
Laboratories). Images were taken using a Leica DC350RX 
camera and Leica Qfluoro software (Leica microsystems 
UK Ltd. Miltom Keynes, UK). For each antibody combi-
nation, control images, in which the primary antibody is 
replaced by 1:400 rabbit immunoglobulin or 1 μg/mL iso-
type matched mouse and rat monoclonal antibodies were 
taken using the same camera settings and showed no spe-
cific staining (see Figure 3D for representative image).
Quantitative reverse transcriptase polymerase chain 
reaction (RT‑QPCR)
Total RNA was isolated from 25 μg tissue stored in RNAl-
ater using a Nuclelospin® RNA II kit (Machery-Nagel) 
following the manufacturer’s instructions including an 
on-column DNAse step. To ensure the complete removal 
of DNA two extra DNAse and re-isolation steps were 
included as previously described [34]. RNA was quanti-
fied using a micro-fluorimiter (Qubit Invitrogen). Fifty 
nano-grams of total RNA from each sample was reverse 
transcribed using ImProm-II™ Reverse Transcriptase 
(Promega) and random hexamer primers according to the 
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manufacturer’s protocol, the resultant cDNA was made 
up to a final volume of 120  μL in water. Five microlitre 
aliquots of cDNA were run in PCR reactions consisting 
of 12.5 μL Gotaq mastermix (Promega), 1.25 μL 50 mM 
MgCl2, 0.5  μL of 10  μM forward and reverse primers 
plus 0.5  μL of the appropriate 10  μM probe conjugated 
to 3′FAM and 5′ BQ1 (Metabion) added to each reaction. 
The primers and probes for multiple housekeeping genes 
and equine cytokines (Additional file  1) were designed 
using primer 3 software [35] with a target melting point 
of 60 °C for primers and 70 °C for probes, optimal 50% CG 
content, polyX <3 and 3′ complementarity ≤1. The prod-
uct for each potential primer pair was analysed to ensure 
the absence of competing secondary structures using 
m-fold [36]. Following an initial PCR to generate DNA 
product, the efficiency of each primer was calculated by 
running a series of ten-fold dilutions of DNA template 
using syber green in place of the probe on a Stratagene 
MX3005P thermal cycler. Cycling conditions of 2 min at 
95  °C followed by 40 cycles of 10  s at 95  °C and 20  s at 
60  °C. The thermal profile for melting curve determina-
tion began with an incubation of 1 min at 60 °C followed 
by a gradual increase in temperature (1  °C/15  s), during 
which time changes in fluorescence were monitored at 
0.5 °C intervals. The resultant melting curve was used to 
confirm the absence of primer dimers and the MXpro 
software used to calculate the efficiency of the reactions.
Each sample was run using every cytokine and house-
keeping gene primer pair in individual reactions. The 
data was normalised using GeNorm software [37] to 
identify the most stable combination of multiple house-
keeping genes which in this case were Actβ, HPRT1, 
RPL32. The normalised data for each individual cytokine 
are expressed as relative copy number, whereby the sam-
ple with the lowest recorded cycle threshold (CT) takes 
the value 1 and all other samples become a multiple of 
this reference value. For the purposes of analysis negative 
samples which did not give a CT (i.e., remained negative 
after 40 cycles) were set to a dummy variable value of 0.
Statistical analysis
The cytokine data was analysed using Kruskal–Wal-
lis analysis of variance; where significant differences 
were detected (p ≤ 0.05), we then used a Man-Whitney 
test with a Bonferroni adjustment of p  <  0.016 to com-
pare cytokine expression between the pairs of tissues 




Immunohistology of formalin fixed tissues confirmed 
the presence of many CD3+ T-cells within sarcoids 
(Figures 1A, B and C). Individual T-cells were distributed 
throughout the tumour, infiltrating between the fibro-
blasts (Figure  1A), at higher power the T-cells had an 
activated blast morphology with the presence of distinct 
membrane staining surrounding an area of cytoplasm 
with a central nucleus. Clusters of CD3 T-cells were 
frequently seen adjacent to blood vessels (Figure  1C). 
Dual staining with rabbit anti-CD3 and donkey anti-
rabbit texas red conjugate, along with mouse monoclo-
nal anti-BPV E2 and goat anti-mouse FITC conjugate 
(Figure 1D) confirmed our earlier observation that BPV 
E2 is expressed within the nuclei of sarcoid tumour cells 
and the CD3 T-cells themselves do not express BPV E2 
antigen. Staining of fixed tissue samples of normal equine 
skin using rabbit anti-FOXP3 (ab10563) did not detect 
any positive cells in the dermis. The keratin layer of the 
healthy epidermis showed a typical diffuse light brown 
non-specific background, and the basal cells contained 
brown melanin granules which make interpretation dif-
ficult using DAB substrate. However the basal cell nuclei 
stained blue with the haematoxylin counterstain indicat-
ing they do not express FOXP3 but some scattered cell 
nuclei in the stratum spinosum were positive (Figure 1E). 
In comparison the majority of nuclei within the sarcoid 
tumour mass expressed FOXP3 (Figure  1F). Moreover 
the nuclei of many basal cells as well as cells in the stra-
tum spinosum of the epidermis overlying the tumour also 
stained positive for FOXP3 (Figure  1F). Further images 
of control slides and data for validation of FOXP3 stain-
ing using ab10563 (abCam, UK) in horses is provided in 
Additional files 3, 4, 5, 6, 7 and 8.
To further characterise the phenotype of the tumour 
infiltrating T-cells, dual staining of sarcoid sections was 
carried out using rabbit anti-CD3 and donkey anti-
rabbit texas red conjugate (Figure  2A) in combination 
with mouse monoclonal anti-equine CD4 and goat anti-
mouse FITC conjugate (Figure  2B). Comparison of the 
combined images shows that the majority of cells express 
both CD-antigens. However, there was considerable var-
iation in the intensity of staining, the combined image 
(Figure  2C) showed a small number of CD3hi CD4hi 
cells which appear yellow or orange, with the remain-
ing cells appearing green indicating that they express 
relatively little CD3 in comparison to CD4 although this 
too appears to be low in intensity on most cells. Occa-
sional CD4+ only cells were also present (green arrows 
Figures 2A and C).
Results from a similar set of images using CD8 in 
place of CD4 are shown in Figure  2D, E and F; the 
majority of CD3+ cells also express CD8, although most 
stain only faintly CD8+. Several CD3+ CD8− cells are 
also present (red arrow). Dual staining using monoclo-
nal antibodies specific for equine CD4 and CD8 along 
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with isotype specific conjugates (Figures  2G, H and 
I) confirmed that the majority of T-cells were CD4lo 
CD8lo dual positive with a small number of CD4hi or 
CD8hi single positive cells visible (green and red arrows 
respectively).
To determine if the sarcoid infiltrating T-cells had a 
regulatory phenotype, sections were stained with rab-
bit anti-FOXP3, in combination with anti-rabbit Texas 
red (Figure  3A) and a mixture of monoclonal mouse-
anti equine CD4 and monoclonal mouse anti-equine 
Figure 1 Immunohistology of sarcoid CD3+ T-cells and FOXP3 expression. A–C Sections of formalin fixed sarcoid tissue stained using 
anti-CD3 antibody and peroxidase anti-rabbit antibodies developed with DAB substrate. A A low power image (×100) Brown CD3+ T-cells are 
present throughout the tumour. B A higher power image (×200) showing the CD3+ positive brown staining of cell membranes surrounding a clear 
cytoplasm and nucleus typical of activated T-cell blasts. C An area of dense T-cell infiltration surrounding a blood vessel (×200). D Frozen section 
of sarcoid tissue showing texas-red CD3+ T-cells and separate green FITC stained BPV E2 superimposed on blue DAPI nuclear staining. E Formalin 
fixed section of normal equine skin stained with rabbit anti-FOXP3 peroxidase using DAB substrate. The nuclei of cells in the dermis do not express 
FOXP3, the epidermis shows a diffuse background staining of the keratin, the basal cells contain brown melanin granules but there nuclei are nega-
tive for FOXP3 and visible with blue counterstain some FOXP3 positive nuclei are present in the stratum spinosum (arrow). F Formalin fixed section 
of equine sarcoid stained with rabbit anti-FOXP3, the majority of nuclei in the tumour are dark brown indicating they express FOXP3. The FOXP3 
staining extends into the nuclei of some basal cells within the epidermis and the stratum spinosum.
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CD8 using anti-mouse FITC conjugates (Figure 3B). The 
results for the combined image confirmed that the CD4+ 
CD8+ cells all expressed FOXP3 (Figure 3C); in addition 
it was noted that many CD4−CD8− tumour cells were 
also FOXP3 positive (Figure 3C) [in agreement with the 
extensive staining seen in fixed tissues (Figure 3F)]. Con-
trol slides, incubated with rabbit and mouse immuno-
globulins, were uniformly unstained (Figure 3D).
Rabbit antibody (ab50163) recognises a peptide at the 
extreme C-terminal of FOXP3 and unexpectedly did not 
detect any positive cells in an uninflamed lymph node, 
but did stain numerous cell nuclei in inflamed lymphoid 
tissue (Additional files 3, 5  and 6). In contrast rat mon-
oclonal anti-mouse Foxp3 which detects an epitope 
mapped to exon 2 of Foxp3 (FJK-16ss) did stain scattered 
lymphocytes in resting lymph nodes from horses but not 
in inflamed lymphoid tissue. Moreover only a few strongly 
positive cells could be detected in formalin fixed sarcoid 
tissue stained using FJK-16s, which mostly appeared 
among lymphoid cell clusters close to blood vessels Addi-
tional file 8, although some signs of a weak staining more 
generally distributed throughout sarcoid tissue were seen, 
prompting further examination of FOXP3 expression in 
frozen sections of sarcoid samples stained with FJK-16s. 
Figure 2 CD4 and CD8 expression on sarcoid T-cells. Cryostat sections from a lymphocyte rich area of sarcoid tissue dual stained with different 
combination of rabbit anti-CD3 and monoclonal mouse anti-equine CD4 or equine CD8α. A–C Frozen tissue sections dual labelled with (A) rabbit 
anti-CD3 (texas red), (B) mouse anti-CD4 (FITC) (C) combined image with DAPI nuclear counterstain, most cells express both CD4 and CD3 although 
some CD4 only cells are present (green arrow). D–F Frozen tissue sections dual stained with (D) rabbit anti-CD3 (texas red), (E) mouse anti-CD8 
(FITC), (F) combined image with DAPI counterstain most cells express both CD3 and CD8 although some CD3 only cells are present (red arrow). G–I 
Frozen tissue sections dual labelled with (G) monoclonal anti-CD8 TRITC and (H) anti-CD4 FITC (F) combined image with DAPI nuclear counterstain, 
the majority of cells are CD4 CD8 dual positive with a few CD8 and CD4 single positive cells (red and green arrows respectively).
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The results confirmed the extensive expression of FOXP3 
in sarcoid tissues (Figure  3E) with the strongest expres-
sion found in CD4+  cells (Figures  3G  and H) although 
some CD4-ve cells also showed positive staining using 
this antibody (Figure 3H). The differences in staining pat-
terns of the two anti FOXP3 antibodies can be accounted 
for if the epitopes recognised by the antibodies in horses, 
are differentially spliced or removed by post translational 
proteolytic processing as has been demonstrated to occur 
in human FOXP3 [38, 39].
As staining with anti CD3 and BPV_E2 (Figure  1C) 
has confirmed our previous finding that T-cells them-
selves are BPV1 negative, this staining pattern sug-
gests that BPV infected cells must express FOXP3. Dual 
staining with mouse anti BPVE2 and rabbit anti-FOXP3 
confirmed that papillomavirus infected tumour cells co-
expressed both antigens in their nuclei (Figure 4).
Both MHC class I and MHC class II antigens were 
expressed on a proportion of cells within sarcoids 
(Figure  5). Many of the MHC II positive cells co-
expressed CD3 (Figures  5A, B and C), and given the 
variable and often weak intensity of CD3 staining it was 
difficult to determine the extent to which non T-cells 
expressing MHC II may be present in sarcoid tissues. 
Similarly MHC class I was also expressed most strongly 
on CD3 positive cells (Figures  5D, E and F). We next 
attempted to determine if MHC I was co-expressed on 
BPV E2 positive tumour cells (Figures 5G, H and I), some 
co-localisation of MHC I and BPV E2 was detected but 
is not possible to say whether this was due to membrane 
surface expression on MHC I on tumour fibroblasts.
RT‑qpcr
The results of the cytokine QPCR are shown in Figure 6. 
Examination of the raw data showed that even though 
equal amounts of mRNA (50  ng per sample) were 
reverse transcribed, most cytokine transcripts were low-
est in skin, intermediate in sarcoid and highest in spleen 
reflecting the increasing numbers of lymphocytes found 
in each tissue. Normalisation of the results using a panel 
of multiple housekeeping genes reduced the magnitude 
of this effect but some differences were still apparent.
For the pro-inflammatory cytokines IL1α and IL6, there 
were no overall significant differences in expression when 
tested by Kruskal-Wallace ANOVA (KW p ≥ 0.05), IL1β 
did differ between the sample groups (KW p = 0.012), but 
post hoc Mann–Whitey testing showed this was attribut-
able to the spleen having a significantly (p < 0.016) higher 
level of expression compared to skin which did not differ 
from sarcoid (Figure 6A).
For the interferons (Figure 6B) there were no significant 
differences in IFNα or IFNβ expression, (KW p ≥ 0.05), 
but IFNγ was significantly different among the groups 
(KW p = 0.0027). Here too post hoc testing showed this 
Figure 3 FOXP3 expression on sarcoid infiltrating T-cells. A Cryostat sections of sarcoid tissue stained with rabbit anti-FOXP3 (ab 10563) and 
donkey anti rabbit texas-red with blue DAPI nuclear counterstain. B Same section stained using both mouse monoclonal anti-CD4 and monoclonal 
anti-CD8α with goat anti mouse FITC conjugate. C Combined image showing CD4 and CD8 stained T-cells and non T-cells all express FOXP3. D 
Specificity control slide stained with normal rabbit immunoglobulin and isotype matched control mouse monoclonal antibody, DAPI counterstain. 
E Cryostat sections of sarcoid tissue stained with rat anti-FOXP3 (FJK-16s) and donkey anti rat FITC with blue DAPI nuclear counterstain. F Same sec-
tion stained using mouse anti equine CD4 with goat anti mouse TRITC conjugate. G Combined image showing both CD4 stained T-cells and non 
T-cells express FOXP3. H Combined image at higher power with CD4-negative FOXP3 positive cells highlighted (arrow).
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was due to the spleen expression levels being signifi-
cantly higher than either skin or sarcoid (Mann–Whitey 
p < 0.016) which again did not differ from each other.
For the IL12 family members (Figure  6C), neither 
IL12p40 nor IL12p35 differed between tissues (KW 
p  ≥  0.05). EBI3 expression did show overall significant 
differences (KW p = 0.028), which once again were due 
to higher levels of expression in spleen compared to 
either skin or sarcoid tissues (Mann–Whitney <0.016).
The expression of regulatory genes (Figure 6D) showed 
highly significant differences detected by Kruskal Wal-
lace, with TGFβ p = 0.001, IL10 p = 0.0017 and FOXP3 
p = 0.005. Post hoc comparisons showed that both TGFβ 
and FOXP3 were higher in the sarcoid compared to skin, 
(TGFβ MW p = 0.004, FOXP3 MW p = 0.006) making 
them the only factors found to be significantly higher in 
sarcoids compared to skin, while the spleen was signifi-
cantly higher than skin but did not differ from sarcoid. 
For IL10 the spleen was significantly higher than either 
skin or sarcoid (MW ≤0.016), but sarcoid and skin did 
not differ from each other.
The remaining cardinal T-cell cytokines all showed sig-
nificant differences between tissues (Figure 6E) Kruskall 
Wallace IL2 p = 0.003, IL4 p = 0.002 and IL17 p = 0.040. 
In the case of IL2 and IL4, post hoc testing indicated 
that this was due to the levels of expression being sig-
nificantly higher in spleen compared to both skin and 
sarcoid (Mann–Whitney p  <  0.016), with no difference 
detected between skin and sarcoid. Although, Kruskall 
Wallace indicated an overall difference in IL17 expres-
sion between the groups (KW p = 0.029), post hoc test-
ing using Mann–Whitney and a Bonferroni adjustment 
of α < 0.016 could not demonstrate which pair of groups 
differed significantly. However the p value of the Mann–
Whitney test between sarcoid and skin was p  =  0.574 
while that of either sarcoid and spleen, or spleen and 
skin was p = 0.020 just short of the Bonferroni corrected 
value of p ≤ 0.016, indicating that the most likely source 
of the difference detected by Kruskall Wallace is a lower 
level of IL17 expression in the spleen compared to the 
other two tissues (Figure 6E).
Discussion
The epidemiology of equine sarcoids indicates that BPV 
is transmissible among animals following prolonged close 
contact [40, 41], implying that it can complete its repli-
cation cycle and produce infectious virus within equine 
hosts. This is supported by observations that equine iso-
lates of BPV1 contain distinct DNA sequence motifs in 
the long control region [28] and within the BPV1 E5, E2 
Figure 4 FOXP3 expression in sarcoid E2 positive tumour cell nuclei. A Sarcoid tissue stained with rabbit anti-FOXP3 texas-red. B Sarcoid 
tissue stained with mouse monoclonal anti-BPV E2 FITC. C dual-stained image with DAPI nuclear counterstain. The majority of nuclei in this image 
are dual positive tumour cells but some FOXP3 only T-cells are present (red arrow). D Higher power image (×1000) of nuclei stained with rabbit 
anti-FOXP3 texas red. E The same nuclei stained with mouse anti-BPV E2 FITC. F Higher power image (1000X oil immersion) of dual FOXP3 texas-red 
and BPV E2 FITC dual-positive sarcoid nuclei, DAPI counterstain.
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and L2 gene [9, 29], indicating that equine subtypes of 
this virus have evolved; yet there has been no convinc-
ing demonstration of infectious virus particles within the 
lesions. Although BPV DNA load and virus early gene 
transcription correlate with lesion severity confirming 
the pivotal role for BPV in the pathogenesis of equine 
sarcoids [42, 43], the persistence of the lesions and appar-
ent absence of an effective anti-viral immune response in 
equine sarcoids contrasts with the spontaneous immune 
rejection of BPV associated skin lesions in the majority of 
infected cattle [3, 16].
Along with the presence of BPV DNA, the aetiology 
of equine sarcoids can be linked to a number of genetic 
traits [44]. Genetic associations are particularly evident 
in relation to MHC genes [45, 46] which together with 
other genes related to immune response play an impor-
tant role in host susceptibility to the development of sar-
coids [47]. In addition to these host genetic factors acting 
through increasing the immune susceptibility of horses 
to BPV in vivo, several features of BPV biology have also 
been demonstrated to down-regulate immune function 
in vitro; including the reduction of MHC I expression on 
the cell surface through its interaction with BPV E5 [30], 
along with BPV E2 and E7 mediated down-regulation of 
Toll like receptor 4 [31].
Few studies have been conducted on the immune 
responses of horses with sarcoids to BPV, but the lim-
ited evidence available suggests that there is no naturally 
occurring antibody to late virus proteins [16, 17], and 
the induction of neutralizing antibodies by vaccination 
did not cause reliable regression of the lesions [48, 49]. 
There is an almost complete lack of information on cell 
mediated responses to BPV in respect of equine sarcoids. 
One recent study has demonstrated the up-regulation of 
FOXP3 and IL10 within sarcoid lesions providing the first 
evidence for regulatory T-cells as a further mechanism to 
explain the lack of immune rejection [32], the study also 
showed IL4 transcription was not increased, but IFNγ 
Figure 5 Sarcoid MHC expression. Frozen sarcoid tissue stained with (A) Mouse monoclonal anti-equine MHC II. Goat anti-mouse FITC. B Rabbit 
anti CD3 donkey anti-rabbit Texas red (C) combined image with DAPI counterstain, the majority of MHC II expressing cells are CD3+ T-cells. D Mouse 
monoclonal anti-equine MHC I. Goat anti-mouse FITC. E Rabbit anti CD3 donkey anti-rabbit Texas red (F) combined image with DAPI counterstain 
the strongly MHC I positive cells are CD3+ T-cells. G Monoclonal anti-BPV E2 goat anti-mouse IgG1 FITC, (H) Monoclonal anti-equine MHC I goat anti 
mouse IgG2a. I Combined image with some possible E2 MHC I dual positive cells (arrow).
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was, suggesting that some effector T-cells are also pre-
sent in sarcoid tissue [32].
In broad agreement with these findings analysis of the 
data from our QPCR prior to normalisation, (in which 
equal amounts of total RNA were reverse transcribed 
Additional file  9), also detected significantly higher lev-
els of FOXP3 and IL10, TGFβ and IFNγ in sarcoids com-
pared to normal skin, with no difference in IL4 and IL2. 
However, this may simply reflect basal transcription by 
the higher number of T-cells within sarcoids compared to 
normal skin, and we therefore included a further set of 
samples from a lymphoid organ (spleen) along with nor-
malisation to multiple housekeeping genes to gain a bet-
ter insight into cytokine transcription after taking partial 
account of the effect of cell number and metabolic activ-
ity of different tissues.
Following normalisation to multiple housekeeping 
genes, the magnitude of the effect seen in respect of IL10 
Figure 6 Quantitiative PCR of cytokine mRNA. Cytokine mRNA expression as relative copy number. A The pro-inflammatory cytokine IL1α did 
not differ significantly between any of the samples. Both IL1β and IL6 were significantly higher in spleen† compared skin but not to sarcoid, skin 
and sarcoid did not differ significantly from each other. B No significant differences in IFNα or IFNβ levels among the samples were detected. IFNγ 
was significantly higher in spleen†† compared to either sarcoid or skin, which were not significantly different from each other. C There were no sig-
nificant differences in IL12-p40 or IL12p35 mRNA between the different tissues while EBI3 (IL27βsubunit) was significantly elevated in the spleen†† 
compared to both skin and sarcoid which were not significantly different from each other. D TGFβ and FOXP3 were present in high copy numbers 
in all tissues there was no difference between sarcoid and spleen but both sarcoid* and spleen† were significantly higher compared to skin. IL10 
was significantly higher in spleen†† compared to skin and sarcoid which in turn did not differ significantly from each other. E T-cell cytokines IL2 
and IL4 were significantly higher in spleen†† compared to skin or sarcoid which were not significantly different from each other. Conversely IL17 
was significantly lower in spleen** than either skin or sarcoid.
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was reduced but TGFβ and FOXP3 transcription in sar-
coids remained clearly above that of skin. Additional evi-
dence for the presence of regulatory T-cells in sarcoids 
was provided by immune-staining which showed that 
FOXP3 protein is ubiquitously present in the nuclei of 
sarcoid infiltrating T-cells as well as within the tumour 
fibroblasts themselves. The high level of TGFβ in all tis-
sues examined is the expected result for the uninflamed 
tissues (spleen and skin) in which TGFβ provides a tol-
erance threshold to maintain immune homeostasis and 
prevent autoimmunity [50] but is somewhat surprising 
for sarcoids, in which a large number of T-cells with blast 
morphology are present and would support the conclu-
sion that the T-cells have a regulatory phenotype contrib-
uting to the high TGFβ.
Other regulatory cytokine pathways may also con-
tribute to the homeostasis of uninflamed tissues; for 
example the levels of IL12 family members were biased 
in favour of EBI3 which along with IL12p35 forms the 
anti-inflammatory cytokine dimer IL27 compared to 
the pro-inflammatory IL12p70 formed by combining 
IL12p35 and IL12p40 [51]; once again the results sup-
port the view that sarcoid cytokine expression resembles 
that of a resting uninflamed tissue. Moreover, following 
normalisation, there was a lack of evidence to support 
any increased expression of alpha and beta interferons 
which could mediate an innate anti-viral response, and 
normalisation eliminated the differences between nor-
mal skin and sarcoid with respect to IFNγ, IL2 and IL4 
the key cytokines from Th1 or Th2 differentiated effector 
T-cells. The exception to this was IL17 which was higher 
in skin and sarcoid compared to spleen (Figure 6D). IL17 
is mainly produced by Th17 cells which are important 
in host defence against fungi and extracellular bacteria 
as well as being involved in the pathogenesis of auto-
immune and chronic inflammatory diseases; but increas-
ing evidence supports a role for Th17 cells in immune 
regulation [52]. Interestingly elevated IL17 production 
by CD4+ T-cells has recently been demonstrated in 
HPV-associated cervical intraepithelial neoplasia [53]. 
Increased IL17 expression by T-cells also occurs in the 
hyperplastic skin lesions of E7 transgenic mice in which 
the HPV16 E7 gene is expressed under control of the K14 
promoter in basal epithelial cells [53]. The authors went 
on to demonstrate that IL17 T-cells suppressed immuno-
logical clearance of HPV E7 transgenic epithelial grafts 
in mice [53], although whether IL17 producing T-cells 
could have a similar suppressive role in equine sarcoids 
cannot be easily determined.
In human papillomavirus associated malignancies, 
there is a strong association between the occurrence of 
regulatory T-cells within the lesions, disease progres-
sion and treatment outcome [54–57]. This paper provides 
further evidence of an important role of regulatory 
T-cells in maintaining the papilloma virus infection of 
equine sarcoids; in which almost all infiltrating T-cells 
stained positive for nuclear FOXP3, the key transcrip-
tion factor for T-reg cells of mammals including horses 
[58–60]. The co-expression of FOXP3 and BPV E2 within 
the virus transformed cells adds an extra dimension to 
its potential role in the pathogenesis of sarcoids. Sev-
eral types of non-lymphoid tumour cells are reported to 
have up-regulated FOXP3 expression in the cell nucleus, 
including pancreas [61], melanoma [62], and epithelial 
cells of papilloma virus associated cervical cancer [63]. 
In  vitro experiments have shown the proliferation of 
activated T-cells to be inhibited in the presence FOXP3-
expressing pancreatic cancer cell lines, indicating that 
tumour cells themselves can directly contribute to an 
immune-regulatory microenvironment; although the 
mechanism by which this was mediated was not defined 
[61]. How BPV genes co-expressed with FOXP3 interact 
and what role (if any) that FOXP3 may have in inducing 
regulatory pathways within sarcoid fibroblasts remains to 
be investigated.
Immunofluorescence staining of sarcoid infiltrat-
ing CD3+  T-cells indicated that in addition to FOXP3 
the majority were CD4+CD8+ dual positive cells and 
expressed MHC class I and class II on their surface. 
CD4+CD8+ dual positive T-cells are most often associ-
ated with immature T-cells within the thymus, but in 
humans extra-thymic CD4+CD8+ dual positive T-cells 
are also found in several chronic pathological inflam-
matory conditions or chronic virus infections and nota-
bly CD4+CD8+ dual positive lymphocytes are present 
in normal human skin [64, 65]. In mice, a population of 
CD4+ CD8αα dual positive T-cells that have a regulatory 
function are present in the intestinal epithelial compart-
ment [66]. In primates and pigs CD4+CD8+ dual positive 
cells represent a population of memory cells derived from 
MHC class II restricted CD4+ precursors which express 
CD8α following activation [67]. Most recently a popula-
tion of CD4+ CD8+ CD25+ FOXP3+ induced T-reg cells 
have been identified in pigs infected with Porcine repro-
ductive and respiratory syndrome virus where their num-
bers correlated with viraemia [68] indicating that they 
too have an immune-regulatory function. The consensus 
of evidence favours extra-thymic dual positive T-cells 
being a result of chronic activation and having a regu-
latory phenotype which also fits well with the observed 
lack of effector cytokine expression seen in sarcoids.
It remains unclear what antigens the T-cells in sarcoids 
may be responding to and how that antigen is presented. 
The majority of MHC class II cells in the tumour appear to 
be T-cells which are not usually considered to be profes-
sional antigen presenting cells. Nevertheless MHC class II 
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is expressed on activated CD3 T-cells in most mammals 
including horses and humans, but not in mice [69, 70]. 
However, the outcome of antigen presentation between 
T-cells is usually one of anergy or apoptosis rather than 
activation and their role in immune responses is thought 
to be largely one of regulation [70] providing a further 
potential avenue of immune regulation in sarcoids.
Overall the evidence indicates that equine sarcoids pro-
vide a regulatory immune microenvironment in which the 
replication of BPV infected fibroblast proceeds unchecked 
by the immune system. This insight can alter many of the 
interpretations placed on prior experiments investigating 
the aetiology and pathogenesis of sarcoids: for example the 
reports of successful transmission of sarcoids by grafting 
tumour explants [13] may now be interpreted as a failure 
to reject the allografted tissue due to its capacity to estab-
lish a tolerogenic cytokine microenvironment, as opposed 
to transmission via de novo virus infection. These insights 
into the nature of sarcoid pathogenesis will also inform our 
interpretation of current and future treatment strategies.
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